Internal medicine

Propensity score matching

Adverse effect

Antibiotics

Biology

Microbiology

Gastroenterology

CYP2C19

Esomeprazole

Helicobacter pylori

Amoxicillin

Cytochrome P450

Metabolism

Medicine

Helicobacter

Inconsistent eradication rates for Helicobacter pylori have been reported worldwide with dual therapy, perhaps owing to the difference in dose administration and treatment duration. This retrospective study aimed to determine whether high-dose dual therapy (HDDT) with different regimens leads to different eradication rates. The study compares the efficacy and safety of HDDT 10-day vs 14-day and investigates the factors that might affect the eradication rates.Two comparable treatment groups were based on propensity score matching (PSM). Patients were divided into two groups based on the therapy they underwent: 10-day HDDT and 14-day HDDT (20 mg esomeprazole and 750 mg amoxicillin, administered four times daily). The eradication rates, adverse events (AEs), patient compliance, CYP2C19 gene polymorphisms, and antibiotic resistance rates of the two groups were compared.The intention to treat (ITT) analysis showed that the eradication rates for 10-day and 14-day groups were 78.4% (95% CI 69.6%-87.2%) and 89.7% (95% CI 83.3%-96.2%; p = .039), respectively, while the per-protocol (PP) eradication rates were 80.0% (95% CI 71.3%-88.7%) and 92.9% (95% CI 87.4%-98.5%; p = .014), respectively. The corresponding drug-related AEs were 6.8% (6/88) and 5.7% (5/88; p = .755). No significant differences were observed between the compliance rates of the two groups. The CYP2C19 gene polymorphism had no effect on the eradication rates of the two groups.The results showed that the 14-day HDDT affords a higher H. pylori eradication rate than the 10-day HDDT.

10‐Day and 14‐day high‐dose dual therapy for the treatment of <i>Helicobacter pylori</i>: A propensity score matching analysis

10‐Day and 14‐day high‐dose dual therapy for the treatment of Helicobacter pylori: A propensity score matching analysis